These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38943664)

  • 1. A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.
    Sehgal K; Serritella A; Liu M; ONeill A; Nangia C; Pappa T; Demeure MJ; Worden FP; Haddad R; Lorch J
    J Clin Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38943664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
    Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
    Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
    Leboulleux S; Kapiteijn E; Litière S; Schöffski P; Godbert Y; Rodien P; Jarzab B; Salvatore D; Zanetta S; Capdevila J; Bastholt L; De La Fouchardiere C; Lalami Y; Bardet S; Cornélis F; Dedecjus M; Links T; Sents W; Schlumberger M; Locati DL; Newbold K
    Front Endocrinol (Lausanne); 2024; 15():1403687. PubMed ID: 39015176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
    Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
    Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
    [No Abstract]   [Full Text] [Related]  

  • 7. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
    Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
    Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenvatinib for Anaplastic Thyroid Cancer.
    Tahara M; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Sasaki T; Suzuki T; Fujino K; Dutcus CE; Takahashi S
    Front Oncol; 2017; 7():25. PubMed ID: 28299283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
    Yu J; Liu Z; Su Y; Peng X; Xie Y
    Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer.
    Lin YS; Zhang X; Wang C; Liu YQ; Guan WM; Liang J
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e3027-e3036. PubMed ID: 33769497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial.
    Chi Y; Zheng X; Zhang Y; Shi F; Cheng Y; Guo Z; Ge M; Qin J; Zhang J; Li Z; Zhou X; Huang R; Chen X; Liu H; Cheng R; Xu Z; Li D; Tang P; Gao M
    Clin Cancer Res; 2023 Oct; 29(20):4047-4056. PubMed ID: 37594724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
    Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
    JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.
    Du W; Shi X; Fang Q; Zhang X; Liu S
    Front Endocrinol (Lausanne); 2022; 13():768028. PubMed ID: 35282451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 16. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
    Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
    J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
    Brose MS; Robinson BG; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Sen S; Oliver JW; Banerjee K; Keam B; Capdevila J
    Cancer; 2022 Dec; 128(24):4203-4212. PubMed ID: 36259380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
    Lin Y; Qin S; Yang H; Shi F; Yang A; Han X; Liu B; Li Z; Ji Q; Tang L; Deng Z; Ding Y; Fu W; Xie X; Li L; He X; Lv Z; Ma Q; Shen Z; Guo Z; Chen Z; Cui Y; Tan J; Gao Z; Jing S; Lu K; Luo X; Zhang Y; Fang Y; Li Z; Cheng Y; Lei S; Luan S; Chen G; Wang G; Wu L; Liu L
    Clin Cancer Res; 2023 Aug; 29(15):2791-2799. PubMed ID: 37184934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Brose MS; Robinson B; Sherman SI; Krajewska J; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Hernando J; Faoro L; Banerjee K; Oliver JW; Keam B; Capdevila J
    Lancet Oncol; 2021 Aug; 22(8):1126-1138. PubMed ID: 34237250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.